文献速递糖尿病

使用工厂校准实时连续血糖监测改善多种族青少年及年轻成人1型糖尿病患者的目标范围内时间和糖化血红蛋白:MILLENNIALS研究

Use of Factory-Calibrated Real-time Continuous Glucose Monitoring Improves Time in Target and HbA1c in a Multiethnic Cohort of Adolescents and Young Adults With Type 1 Diabetes: The MILLENNIALS Study.
PubMed 文献 · Diabetes Care · 2020-07-28

该随机交叉试验在16-24岁1型糖尿病患者中比较Dexcom G6实时连续血糖监测(CGM)与自我血糖监测(SMBG),两个8周研究期。CGM期间目标范围内时间(35.7% vs 24.6%)、糖化血红蛋白(降低0.76%)均优于对照,低血糖时间低且两期相当。

要点

  • CGM组目标范围内时间70-180 mg/dL为35.7%,显著高于对照组的24.6%。
  • CGM组平均传感器葡萄糖和高于范围时间均低于对照组。
  • CGM组HbA1c较对照组降低0.76%(8.5 mmol/mol),低血糖时间低且两期相当。

核心结论

  • 在年轻1型糖尿病患者中,与SMBG相比,使用CGM改善目标范围内时间和HbA1c水平。

研究设计与样本

  • 随机交叉试验,纳入16-24岁1型糖尿病患者,比较Dexcom G6 CGM系统与SMBG,随机顺序分配至两个8周研究期。
  • 对照期开始时、第4周和第7周各佩戴盲法CGM 10天;入组后及每个治疗期前后测量HbA1c。
  • 主要结局为目标范围内时间70-180 mg/dL。

主要发现

  • CGM期目标范围内时间显著高于对照期(35.7 ± 13.5% vs 24.6 ± 9.3%;平均差异11.1% [95%CI 7.0-15.2];P < 0.001)。
  • CGM期平均传感器葡萄糖低于对照期(219.7 ± 37.6 mg/dL vs 251.9 ± 36.3 mg/dL;平均差异-32.2 mg/dL [95%CI -44.5至-20.0];P < 0.001)。
  • CGM期高于范围时间低于对照期(61.7 ± 15.1% vs 73.6 ± 10.4%;平均差异11.9% [95%CI -16.4至-7.4];P < 0.001)。
  • HbA1c降低0.76%(95%CI -1.1至-0.4)(-8.5 mmol/mol [95%CI -12.4至-4.6];P < 0.001)。
  • 低于范围时间(<70 mg/dL和<54 mg/dL)在两研究期均较低且相当;CGM期传感器佩戴率为84%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: International type 1 diabetes registries have shown that HbA1c levels are highest in young people with type 1 diabetes; however, improving their glycemic control remains a challenge. We propose that use of the factory-calibrated Dexcom G6 CGM system would improve glycemic control in this cohort. RESEARCH DESIGN AND METHODS: We conducted a randomized crossover trial in young people with type 1 diabetes (16-24 years old) comparing the Dexcom G6 CGM system and self-monitoring of blood glucose (SMBG). Participants were assigned to the interventions in random order during two 8-week study periods. During SMBG, blinded continuous glucose monitoring (CGM) was worn by each participant for 10 days at the start, week 4, and week 7 of the control period. HbA1c measurements were drawn after enrollment and before and after each treatment period. The primary outcome was time in range 70-180 mg/dL. RESULTS: Time in range was significantly higher during CGM compared with control (35.7 ± 13.5% vs. 24.6 ± 9.3%; mean difference 11.1% [95% CI 7.0-15.2]; P < 0.001). CGM use reduced mean sensor glucose (219.7 ± 37.6 mg/dL vs. 251.9 ± 36.3 mg/dL; mean difference -32.2 mg/dL [95% CI -44.5 to -20.0]; P < 0.001) and time above range (61.7 ± 15.1% vs. 73.6 ± 10.4%; mean difference 11.9% [95% CI -16.4 to -7.4]; P < 0.001). HbA1c level was reduced by 0.76% (95% CI -1.1 to -0.4) (-8.5 mmol/mol [95% CI -12.4 to -4.6]; P < 0.001). Times spent below range (<70 mg/dL and <54 mg/dL) were low and comparable during both study periods. Sensor wear was 84% during the CGM period. CONCLUSIONS: CGM use in young people with type 1 diabetes improves time in target and HbA1c levels compared with SMBG.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Thabit H, Prabhu JN, Mubita W, et al. Use of Factory-Calibrated Real-time Continuous Glucose Monitoring Improves Time in Target and HbA1c in a Multiethnic Cohort of Adolescents and Young Adults With Type 1 Diabetes: The MILLENNIALS Study. Diabetes Care. 2020. PMID: 32723843. doi:10.2337/dc20-0736

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。